G. Gravis, K. Fizazi, and J. F. , Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial, Lancet Oncol, vol.14, issue.2, pp.149-58, 2013.

N. D. James, M. R. Sydes, and N. W. Clarke, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, vol.387, pp.1163-77, 2015.

C. J. Sweeney, Y. H. Chen, and M. Carducci, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, vol.373, issue.8, pp.737-783, 2015.

S. Halabi, W. K. Kelly, and H. Ma, Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer, J Clin Oncol, vol.34, issue.14, pp.1652-1661, 2016.

F. Lamothe, J. Kovi, and M. Y. Heshmat, Dissemination of prostatic carcinoma: an autopsy study, J Natl Med Assoc, vol.78, issue.11, pp.1083-1089, 1986.

L. Bubendorf, A. Schöpfer, and U. Wagner, Metastatic patterns of prostate cancer : an autopsy study of 1,589 patients, Hum Pathol, vol.31, issue.5, pp.578-83, 2000.

C. J. Ryan, M. R. Smith, and J. S. De-bono, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, vol.368, issue.2, p.30, 2012.

K. Fizazi, R. Jones, and S. Oudard, Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5, J Clin Oncol, vol.33, issue.7, pp.723-754, 2015.

T. M. Beer, B. Tombal, S. Gillessen, G. Attard, and T. M. Beer, Enzalutamide in metastatic prostate cancer before chemotherapy, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.371, pp.178-211, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02169779

H. I. Scher, K. Fizazi, and F. Saad, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

D. Bono, J. S. Logothetis, C. J. Molina, and A. , Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, vol.364, issue.21, pp.1995-2005, 2011.

A. J. Armstrong, E. S. Garrett-mayer, and Y. C. Yang, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res, vol.13, pp.6396-403, 2007.

K. N. Chi, T. Kheoh, and C. J. Ryan, A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, vol.27, issue.3, pp.454-60, 2015.

Y. Loriot, K. Fizazi, and J. S. De-bono, Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes -31 -from the randomized controlled phase 3 AFFIRM trial. Cancer, vol.123, pp.253-262, 2016.

W. K. Kelly, S. Halabi, and M. A. Carducci, Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients, J Clin Oncol, vol.30, 2012.

S. Halabi, E. J. Small, and P. W. Kantoff, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, 2003.

, Apr, vol.1, issue.7, pp.1232-1239

S. Halabi, C. Y. Lin, and E. J. Small, Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, vol.105, issue.22, pp.1729-1766, 2013.

G. R. Pond and G. Sonpavde, The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, vol.65, issue.1, pp.3-6, 2013.

S. Halabi, C. Y. Lin, and W. K. Kelly, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castrationresistant prostate cancer, J Clin Oncol, vol.32, issue.7, pp.671-678, 2014.

J. M. Fitzpatrick, J. Bellmunt, and F. , Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel, Eur J Cancer, vol.50, issue.9, pp.1617-1644, 2014.

A. Horwich, J. Hugosson, and T. De-reijke, ESMO Consensus Conference Guidelines, vol.24, p.32, 2009.

S. Gillessen, G. Attard, and T. M. Beer, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, pp.178-211, 2017.

S. Gillessen, G. Attard, and T. M. Beer, Management of Patients with Advanced Prostate Cancer : The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, pp.178-211, 2017.

A. Horwich, J. Hugosson, and T. De-reijke, ESMO Consensus Conference Guidelines, vol.24, pp.1141-62, 2009.

J. M. Fitzpatrick, J. Bellmunt, and F. , Optimal management of metastatic castration-resistant prostate cancer : highlights from a European Expert Consensus Panel, Eur J Cancer, vol.50, issue.9, p.37, 2014.

G. Gravis, K. Fizazi, and J. F. , Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15) : a randomised, open-label, phase 3 trial, Lancet Oncol, vol.14, issue.2, pp.149-58, 2013.

N. D. James, M. R. Sydes, and N. W. Clarke, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, vol.387, pp.1163-77, 2015.

C. J. Sweeney, Y. H. Chen, and M. Carducci, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, vol.373, issue.8, pp.737-783, 2015.

F. Lamothe, J. Kovi, and M. Y. Heshmat, Dissemination of prostatic carcinoma: an autopsy study, J Natl Med Assoc, vol.78, issue.11, pp.1083-1089, 1986.

L. Bubendorf, A. Schöpfer, and U. Wagner, Metastatic patterns of prostate cancer : an autopsy study of 1,589 patients, Hum Pathol, vol.31, issue.5, pp.578-83, 2000.

A. J. Armstrong, E. S. Garrett-mayer, and Y. C. Yang, A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer : a TAX327 study analysis. Clin Cancer Res, vol.13, pp.6396-403, 2007.

K. N. Chi, T. Kheoh, and C. J. Ryan, A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel, Ann Oncol, vol.27, issue.3, pp.454-60, 2015.

Y. Loriot, K. Fizazi, and J. S. De-bono, Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer, vol.123, pp.253-262, 2016.

W. K. Kelly, S. Halabi, and M. A. Carducci, Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients, J Clin Oncol, vol.30, 2012.

S. Halabi, W. K. Kelly, and H. Ma, Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer, p.38

, J Clin Oncol, vol.34, issue.14, pp.1652-1661, 2016.

S. Halabi, E. J. Small, and P. W. Kantoff, Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer, J Clin Oncol, vol.21, issue.7, pp.1232-1239, 2003.

S. Halabi, C. Y. Lin, and E. J. Small, Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy, J Natl Cancer Inst, vol.105, issue.22, pp.1729-1766, 2013.

G. R. Pond and G. Sonpavde, The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer, Eur Urol, vol.65, issue.1, pp.3-6, 2013.

S. Halabi, C. Y. Lin, and W. K. Kelly, Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castrationresistant prostate cancer, J Clin Oncol, vol.32, issue.7, pp.671-678, 2014.

C. J. Ryan, M. R. Smith, and J. S. De-bono, Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, vol.368, issue.2, pp.138-186, 2012.

K. Fizazi, R. Jones, and S. Oudard, Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5, J Clin Oncol, vol.33, issue.7, pp.723-754, 2015.

H. I. Scher, K. Fizazi, and F. Saad, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

D. Bono, J. S. Logothetis, C. J. Molina, and A. , Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, vol.364, issue.21, pp.1995-2005, 2011.

T. M. Beer and B. Tombal, Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, vol.371, issue.18, pp.1755-1761, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02169779